安龙生物

北京安龙生物医药有限公司（以下简称安龙生物）成立于2019年8月，注册在昌平区沙河镇，注册资本150万元。安龙生物专注于医药生命科学领域，精专于生物医药尤其是基因治疗方向。公司团队具有高端科研、跨国公司、创业及投资经验，是海归与本土经验的结合，具有极强的生命科学与医药健康专业背景，在生物医药及基因治疗领域曾与欧美企业有丰富的合作经验。基于泰格医药及中国科学院6000万的资金支持，安龙生物立志成为中国基因治疗优秀企业。 Bio focuses on breakthroughs in nucleic acid drugs, including gene therapy, gene regulation, gene editing, other new drug research development technologies, is determined to become a leading company in nucleic acid drugs in China. The company’s core team has domestic foreign scientific research, multinational pharmaceutical companies, entrepreneurship, investment experience.Anlong Bio develops independent intellectual property rights in fields with huge market potential, most of which are in the forefront of China. In the field of rare diseases, Enron Bio uses the abundant resources of rare disease patients in China actively cooperates with foreign companies. At the beginning of its establishment, the company received 60 million yuan in angel financing led by Tigermed, in June 2021, it received hundreds of millions of yuan in Series A financing from CITIC Medical Honghui Capital.